Mariner
PTGX icon

Mariner’s Protagonist Therapeutics PTGX Stock Holding History

Mariner’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$581K Buy
4,738
+1,963
+71% +$205K ﹤0.01% 2353
2026
Q1 		$292K Sell
2,775
-4,845
-64% -$429K ﹤0.01% 2903
2025
Q4 		$666K Sell
7,620
-5,931
-44% -$485K ﹤0.01% 2249
2025
Q3 		$900K Sell
13,551
-2,150
-14% -$122K ﹤0.01% 1997
2025
Q2 		$868K Sell
15,701
-930
-6% -$44.6K ﹤0.01% 1901
2025
Q1 		$804K Sell
16,631
-1,352
-8% -$56.7K ﹤0.01% 1839
2024
Q4 		$694K Buy
17,983
+2,004
+13% +$87.4K ﹤0.01% 1912
2024
Q3 		$719K Buy
15,979
+3,696
+30% +$149K ﹤0.01% 1859
2024
Q2 		$426K Sell
12,283
-441
-3% -$12.9K ﹤0.01% 2167
2024
Q1 		$368K Buy
12,724
+3,470
+37% +$94.4K ﹤0.01% 2268
2023
Q4 		$212K Sell
9,254
-5,288
-36% -$92.5K ﹤0.01% 2647
2023
Q3 		$243K Buy
14,542
+3,708
+34% +$72K ﹤0.01% 2345
2023
Q2 		$299K Sell
10,834
-3,238
-23% -$81K ﹤0.01% 2119
2023
Q1 		$324K Buy
14,072
+3,423
+32% +$57.5K ﹤0.01% 2008
2022
Q4 		$116K Sell
10,649
-2,458
-19% -$20.7K ﹤0.01% 2488
2022
Q3 		$110K Buy
+13,107
New +$124K ﹤0.01% 2184

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Mariner's PTGX Position: Q2 2026 in Review

Mariner increased its Protagonist Therapeutics (PTGX) stake by 71% in Q2 2026, buying an estimated $205K and bringing the position to 4,738 shares worth $581K. The position accounts for ﹤0.01% of the portfolio, ranked #2353.

Mariner first reported a position in PTGX in Q3 2022 and has held it in 16 quarters since. The position peaked at $900K in Q3 2025. 344 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Mariner held 4,738 shares of Protagonist Therapeutics worth $581K as of Q2 2026.
  • Mariner bought 1,963 Protagonist Therapeutics shares in Q2 2026, an estimated $205K.
  • Protagonist Therapeutics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2353 holding.
  • Mariner first reported a position in Protagonist Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Mariner's Protagonist Therapeutics position peaked at $900K in Q3 2025.
  • 344 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.